Which has preferable valuation & earnings, ELVN or SVRA?

Enliven Therapeutics is trading at a lower price-to-earnings ratio than Savara, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Enliven Therapeutics N/A N/A -$103.69M -$1.67 N/A Savara N/A N/A -$118.84M -$0.58 N/A

Is ELVN or SVRA more profitable?

Enliven Therapeutics' return on equity of -18.55% beat Savara's return on equity. Company Net Margins Return on Equity Return on Assets Enliven Therapeutics N/A -18.55% -18.09% Savara N/A -90.28% -68.95%

Does the media favor ELVN or SVRA?

In the previous week, Enliven Therapeutics had 6 more articles in the media than Savara. MarketBeat recorded 8 mentions for Enliven Therapeutics and 2 mentions for Savara. Savara's average media sentiment score of 1.79 beat Enliven Therapeutics' score of 1.46 indicating that Savara is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Enliven Therapeutics 7 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Savara 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Is SVRA or RLAY more profitable?

Relay Therapeutics' return on equity of -42.27% beat Savara's return on equity. Company Net Margins Return on Equity Return on Assets Savara N/A -90.28% -68.95% Relay Therapeutics N/A -42.27% -38.67%

Does the media refer more to SVRA or RLAY?

In the previous week, Relay Therapeutics had 7 more articles in the media than Savara. MarketBeat recorded 9 mentions for Relay Therapeutics and 2 mentions for Savara. Savara's average media sentiment score of 1.79 beat Relay Therapeutics' score of 1.28 indicating that Savara is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Savara 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Relay Therapeutics 8 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is SVRA or LEGN more profitable?

Savara has a net margin of 0.00% compared to Legend Biotech's net margin of -7.21%. Legend Biotech's return on equity of -8.71% beat Savara's return on equity. Company Net Margins Return on Equity Return on Assets Savara N/A -90.28% -68.95% Legend Biotech -7.21% -8.71% -5.40%

Does the media prefer SVRA or LEGN?

In the previous week, Legend Biotech had 4 more articles in the media than Savara. MarketBeat recorded 6 mentions for Legend Biotech and 2 mentions for Savara. Savara's average media sentiment score of 1.79 beat Legend Biotech's score of 0.50 indicating that Savara is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Savara 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Legend Biotech 2 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has preferable valuation & earnings, SVRA or VKTX?

Savara is trading at a lower price-to-earnings ratio than Viking Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Savara N/A N/A -$118.84M -$0.58 N/A Viking Therapeutics N/A N/A -$359.64M -$4.66 N/A

Is SVRA or VKTX more profitable?

Savara's return on equity of -90.28% beat Viking Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Savara N/A -90.28% -68.95% Viking Therapeutics N/A -94.56% -82.75%

Does the media refer more to SVRA or VKTX?

In the previous week, Viking Therapeutics had 12 more articles in the media than Savara. MarketBeat recorded 14 mentions for Viking Therapeutics and 2 mentions for Savara. Savara's average media sentiment score of 1.79 beat Viking Therapeutics' score of 1.01 indicating that Savara is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Savara 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Viking Therapeutics 9 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 1 Very Negative mention(s) Positive

Is SVRA or TNGX more profitable?

Tango Therapeutics' return on equity of -25.75% beat Savara's return on equity. Company Net Margins Return on Equity Return on Assets Savara N/A -90.28% -68.95% Tango Therapeutics N/A -25.75% -23.36%

Does the media refer more to SVRA or TNGX?

In the previous week, Savara and Savara both had 2 articles in the media. Savara's average media sentiment score of 1.79 beat Tango Therapeutics' score of 0.98 indicating that Savara is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Savara 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Tango Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Savara (SVRA) Competitors

$5.53 +0.16 (+2.98%)

Closing price 09/8/2026 04:00 PM Eastern

Extended Trading

$5.61 +0.08 (+1.45%)

As of 09/8/2026 07:52 PM Eastern

Compare

SVRA vs. ELVN, RLAY, LEGN, VKTX, and TNGX

Should you buy Savara stock or one of its competitors? Savara's main competitors and comparable companies include Enliven Therapeutics (ELVN), Relay Therapeutics (RLAY), Legend Biotech (LEGN), Viking Therapeutics (VKTX), and Tango Therapeutics (TNGX). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Savara compare to Enliven Therapeutics?

Enliven Therapeutics (NASDAQ:ELVN) and Savara (NASDAQ:SVRA) are both healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their risk, media sentiment, profitability, institutional ownership, valuation, earnings, analyst recommendations and dividends.

In the previous week, Enliven Therapeutics had 6 more articles in the media than Savara. MarketBeat recorded 8 mentions for Enliven Therapeutics and 2 mentions for Savara. Savara's average media sentiment score of 1.79 beat Enliven Therapeutics' score of 1.46 indicating that Savara is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Enliven Therapeutics	7 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Savara	2 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

Enliven Therapeutics' return on equity of -18.55% beat Savara's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Enliven Therapeutics	N/A	-18.55%	-18.09%
Savara	N/A	-90.28%	-68.95%

Enliven Therapeutics presently has a consensus price target of $75.00, indicating a potential upside of 26.33%. Savara has a consensus price target of $10.00, indicating a potential upside of 80.83%. Given Savara's stronger consensus rating and higher probable upside, analysts plainly believe Savara is more favorable than Enliven Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Enliven Therapeutics	1 Sell rating(s)	0 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.78
Savara	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.88

Enliven Therapeutics is trading at a lower price-to-earnings ratio than Savara, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Enliven Therapeutics	N/A	N/A	-$103.69M	-$1.67	N/A
Savara	N/A	N/A	-$118.84M	-$0.58	N/A

Enliven Therapeutics has a beta of 0.3, meaning that its stock price is 70% less volatile than the broader market. Comparatively, Savara has a beta of 0.25, meaning that its stock price is 75% less volatile than the broader market.

95.1% of Enliven Therapeutics shares are owned by institutional investors. Comparatively, 87.9% of Savara shares are owned by institutional investors. 3.0% of Enliven Therapeutics shares are owned by insiders. Comparatively, 5.3% of Savara shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Summary

Enliven Therapeutics and Savara tied by winning 7 of the 14 factors compared between the two stocks.

How does Savara compare to Relay Therapeutics?

Savara (NASDAQ:SVRA) and Relay Therapeutics (NASDAQ:RLAY) are both healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their dividends, valuation, profitability, earnings, institutional ownership, analyst recommendations, risk and media sentiment.

Savara presently has a consensus price target of $10.00, indicating a potential upside of 80.83%. Relay Therapeutics has a consensus price target of $25.92, indicating a potential upside of 35.62%. Given Savara's higher possible upside, equities analysts plainly believe Savara is more favorable than Relay Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Savara	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.88
Relay Therapeutics	1 Sell rating(s)	1 Hold rating(s)	10 Buy rating(s)	2 Strong Buy rating(s)	2.93

Savara has a beta of 0.25, suggesting that its share price is 75% less volatile than the broader market. Comparatively, Relay Therapeutics has a beta of 1.69, suggesting that its share price is 69% more volatile than the broader market.

87.9% of Savara shares are owned by institutional investors. Comparatively, 97.0% of Relay Therapeutics shares are owned by institutional investors. 5.3% of Savara shares are owned by company insiders. Comparatively, 5.0% of Relay Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

In the previous week, Relay Therapeutics had 7 more articles in the media than Savara. MarketBeat recorded 9 mentions for Relay Therapeutics and 2 mentions for Savara. Savara's average media sentiment score of 1.79 beat Relay Therapeutics' score of 1.28 indicating that Savara is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Savara	2 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Relay Therapeutics	8 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Relay Therapeutics' return on equity of -42.27% beat Savara's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Savara	N/A	-90.28%	-68.95%
Relay Therapeutics	N/A	-42.27%	-38.67%

Savara has higher earnings, but lower revenue than Relay Therapeutics. Relay Therapeutics is trading at a lower price-to-earnings ratio than Savara, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Savara	N/A	N/A	-$118.84M	-$0.58	N/A
Relay Therapeutics	$10.35M	404.62	-$276.48M	-$1.57	N/A

Summary

Relay Therapeutics beats Savara on 9 of the 15 factors compared between the two stocks.

How does Savara compare to Legend Biotech?

Savara (NASDAQ:SVRA) and Legend Biotech (NASDAQ:LEGN) are both healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their profitability, institutional ownership, media sentiment, earnings, risk, analyst recommendations, dividends and valuation.

In the previous week, Legend Biotech had 4 more articles in the media than Savara. MarketBeat recorded 6 mentions for Legend Biotech and 2 mentions for Savara. Savara's average media sentiment score of 1.79 beat Legend Biotech's score of 0.50 indicating that Savara is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Savara	2 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Legend Biotech	2 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Savara currently has a consensus target price of $10.00, indicating a potential upside of 80.83%. Legend Biotech has a consensus target price of $53.43, indicating a potential upside of 160.75%. Given Legend Biotech's higher possible upside, analysts plainly believe Legend Biotech is more favorable than Savara.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Savara	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.88
Legend Biotech	1 Sell rating(s)	6 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.47

Savara has higher earnings, but lower revenue than Legend Biotech. Legend Biotech is trading at a lower price-to-earnings ratio than Savara, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Savara	N/A	N/A	-$118.84M	-$0.58	N/A
Legend Biotech	$1.27B	3.12	-$296.80M	-$0.25	N/A

Savara has a net margin of 0.00% compared to Legend Biotech's net margin of -7.21%. Legend Biotech's return on equity of -8.71% beat Savara's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Savara	N/A	-90.28%	-68.95%
Legend Biotech	-7.21%	-8.71%	-5.40%

87.9% of Savara shares are held by institutional investors. Comparatively, 70.9% of Legend Biotech shares are held by institutional investors. 5.3% of Savara shares are held by company insiders. Comparatively, 0.0% of Legend Biotech shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Savara has a beta of 0.25, suggesting that its stock price is 75% less volatile than the broader market. Comparatively, Legend Biotech has a beta of 0.4, suggesting that its stock price is 60% less volatile than the broader market.

Summary

Savara and Legend Biotech tied by winning 8 of the 16 factors compared between the two stocks.

How does Savara compare to Viking Therapeutics?

Savara (NASDAQ:SVRA) and Viking Therapeutics (NASDAQ:VKTX) are both healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, media sentiment, dividends, analyst recommendations, earnings, risk, profitability and valuation.

Savara's return on equity of -90.28% beat Viking Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Savara	N/A	-90.28%	-68.95%
Viking Therapeutics	N/A	-94.56%	-82.75%

Savara is trading at a lower price-to-earnings ratio than Viking Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Savara	N/A	N/A	-$118.84M	-$0.58	N/A
Viking Therapeutics	N/A	N/A	-$359.64M	-$4.66	N/A

In the previous week, Viking Therapeutics had 12 more articles in the media than Savara. MarketBeat recorded 14 mentions for Viking Therapeutics and 2 mentions for Savara. Savara's average media sentiment score of 1.79 beat Viking Therapeutics' score of 1.01 indicating that Savara is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Savara	2 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Viking Therapeutics	9 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	1 Very Negative mention(s)	Positive

87.9% of Savara shares are owned by institutional investors. Comparatively, 76.0% of Viking Therapeutics shares are owned by institutional investors. 5.3% of Savara shares are owned by company insiders. Comparatively, 5.3% of Viking Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Savara has a beta of 0.25, indicating that its share price is 75% less volatile than the broader market. Comparatively, Viking Therapeutics has a beta of 0.69, indicating that its share price is 31% less volatile than the broader market.

Savara presently has a consensus price target of $10.00, indicating a potential upside of 80.83%. Viking Therapeutics has a consensus price target of $96.63, indicating a potential upside of 186.89%. Given Viking Therapeutics' higher probable upside, analysts clearly believe Viking Therapeutics is more favorable than Savara.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Savara	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.88
Viking Therapeutics	1 Sell rating(s)	2 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.75

Summary

Savara beats Viking Therapeutics on 7 of the 12 factors compared between the two stocks.

How does Savara compare to Tango Therapeutics?

Savara (NASDAQ:SVRA) and Tango Therapeutics (NASDAQ:TNGX) are both healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, profitability, valuation, risk, earnings, media sentiment, institutional ownership and dividends.

Tango Therapeutics has higher revenue and earnings than Savara. Tango Therapeutics is trading at a lower price-to-earnings ratio than Savara, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Savara	N/A	N/A	-$118.84M	-$0.58	N/A
Tango Therapeutics	$53.81M	71.13	-$101.59M	-$0.85	N/A

Tango Therapeutics' return on equity of -25.75% beat Savara's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Savara	N/A	-90.28%	-68.95%
Tango Therapeutics	N/A	-25.75%	-23.36%

Savara has a beta of 0.25, indicating that its stock price is 75% less volatile than the broader market. Comparatively, Tango Therapeutics has a beta of 1.12, indicating that its stock price is 12% more volatile than the broader market.

Savara currently has a consensus price target of $10.00, suggesting a potential upside of 80.83%. Tango Therapeutics has a consensus price target of $43.46, suggesting a potential upside of 91.46%. Given Tango Therapeutics' higher probable upside, analysts clearly believe Tango Therapeutics is more favorable than Savara.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Savara	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.88
Tango Therapeutics	1 Sell rating(s)	2 Hold rating(s)	13 Buy rating(s)	0 Strong Buy rating(s)	2.75

In the previous week, Savara and Savara both had 2 articles in the media. Savara's average media sentiment score of 1.79 beat Tango Therapeutics' score of 0.98 indicating that Savara is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Savara	2 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Tango Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

87.9% of Savara shares are held by institutional investors. Comparatively, 79.0% of Tango Therapeutics shares are held by institutional investors. 5.3% of Savara shares are held by company insiders. Comparatively, 6.5% of Tango Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Summary

Tango Therapeutics beats Savara on 8 of the 14 factors compared between the two stocks.

Get Savara News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding SVRA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

SVRA vs. The Competition

Export

Metric	Savara	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$1.10B	$4.01B	$7.38B	$12.88B
Dividend Yield	N/A	3.60%	2.54%	9.14%
P/E Ratio	-9.53	12.50	270.68	25.39
Price / Sales	N/A	1,514.31	666.23	108.57
Price / Cash	N/A	108.60	77.07	52.39
Price / Book	5.53	15.97	10.88	6.40
Net Income	-$118.84M	-$22.81M	$3.48B	$358.18M
7 Day Performance	1.28%	-0.85%	-0.97%	0.04%
1 Month Performance	-5.15%	4.84%	2.92%	-0.80%
1 Year Performance	44.76%	47.27%	22.20%	12.47%

Savara Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
SVRA Savara	2.2889 of 5 stars	$5.53 +3.0%	$10.00 +80.8%	+43.6%	$1.10B	N/A	N/A	20	Positive News
ELVN Enliven Therapeutics	2.8149 of 5 stars	$57.84 -0.1%	$75.00 +29.7%	+196.6%	$4.22B	N/A	N/A	50	Positive News
RLAY Relay Therapeutics	2.7584 of 5 stars	$18.42 +0.2%	$25.92 +40.7%	+370.7%	$4.04B	$15.35M	N/A	330	Positive News
LEGN Legend Biotech	3.1339 of 5 stars	$20.79 +0.1%	$52.29 +151.5%	-40.8%	$4.03B	$1.03B	N/A	2,965
VKTX Viking Therapeutics	3.1172 of 5 stars	$32.44 -1.0%	$96.63 +197.9%	+32.2%	$3.78B	N/A	N/A	20

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:SVRA) was last updated on 9/9/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Savara (SVRA) Competitors

SVRA vs. ELVN, RLAY, LEGN, VKTX, and TNGX

How does Savara compare to Enliven Therapeutics?

Summary

How does Savara compare to Relay Therapeutics?

Summary

How does Savara compare to Legend Biotech?

Summary

How does Savara compare to Viking Therapeutics?

Summary

How does Savara compare to Tango Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SVRA vs. The Competition

Savara Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Savara (SVRA) Competitors

SVRA vs. ELVN, RLAY, LEGN, VKTX, and TNGX

How does Savara compare to Enliven Therapeutics?

Does the media favor ELVN or SVRA?

Is ELVN or SVRA more profitable?

Do analysts rate ELVN or SVRA?

Which has preferable valuation & earnings, ELVN or SVRA?

Which has more risk and volatility, ELVN or SVRA?

Do insiders and institutionals believe in ELVN or SVRA?

Summary

How does Savara compare to Relay Therapeutics?

Do analysts rate SVRA or RLAY?

Which has more risk & volatility, SVRA or RLAY?

Do institutionals & insiders believe in SVRA or RLAY?

Does the media refer more to SVRA or RLAY?

Is SVRA or RLAY more profitable?

Which has preferable earnings & valuation, SVRA or RLAY?

Summary

How does Savara compare to Legend Biotech?

Does the media prefer SVRA or LEGN?

Do analysts rate SVRA or LEGN?

Which has higher earnings & valuation, SVRA or LEGN?

Is SVRA or LEGN more profitable?

Do insiders & institutionals believe in SVRA or LEGN?

Which has more risk & volatility, SVRA or LEGN?

Summary

How does Savara compare to Viking Therapeutics?

Is SVRA or VKTX more profitable?

Which has preferable valuation & earnings, SVRA or VKTX?

Does the media refer more to SVRA or VKTX?

Do insiders & institutionals have more ownership in SVRA or VKTX?

Which has more volatility and risk, SVRA or VKTX?

Do analysts prefer SVRA or VKTX?

Summary

How does Savara compare to Tango Therapeutics?

Which has better earnings & valuation, SVRA or TNGX?

Is SVRA or TNGX more profitable?

Which has more volatility & risk, SVRA or TNGX?

Do analysts prefer SVRA or TNGX?

Does the media refer more to SVRA or TNGX?

Do insiders and institutionals hold more shares of SVRA or TNGX?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SVRA vs. The Competition

Savara Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools